STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer

September 16-21, 2021; Virtual
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 250 KB
Released: September 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), experts discuss advances in prostate cancer treatment, including use of GnRH antagonists and androgen receptor inhibitors.

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD, MPH Released: November 2, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue